Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by Columbia University.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Columbia University
ClinicalTrials.gov Identifier:
NCT00104585
First received: March 1, 2005
Last updated: January 18, 2012
Last verified: January 2012
  Purpose
The purpose of this study is to investigate genetic and environmental risk factors that increase susceptibility to the development of early-onset Parkinson's disease (developed at or before age 50).

Condition
Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Cross-Sectional
Official Title: Genetic Epidemiology of Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Columbia University:

Biospecimen Retention:   Samples With DNA
whole blood

Estimated Enrollment: 800
Study Start Date: July 2004
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
People with young onset Parkinson's disease and their family members

Detailed Description:

Parkinson's disease (PD) is a common, neurodegenerative condition. Although mostly a late-onset disorder, 10 percent of people with PD are reported to develop symptoms before the age of 50. To date, six genes have been found to be associated with PD, however the majority have been found in rare PD 'families'. Some studies have also identified a number of environmental risk factors, such as pesticide use, that appear to increase the risk of PD.

In a previous study, Dr. Karen Marder and her research team found that close family members of people with both early- and late-onset PD have a three-fold increased risk of PD compared to close family members of people without PD.

The purpose of the Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) study is to identify the genetic factors that contribute to the development of early-onset Parkinson's disease, and to understand how these genetic factors interact with other genes and the environment to cause PD.

Participation in the study involves a blood draw (to look for genetic factors associated with PD), questionnaires collecting information on family and medical history, and a neurological examination. In addition participants may be contacted in the future and asked to participate in a more detailed interview. At that time, study investigators will also ask participants for permission to contact family members to invite them to participate in the study.

This research study requires participants to sign a consent form, which states that the research is voluntary and confidential. In addition, since this is a research study, genetic results are not released to participants or their family members now or in the future.

Scientists hope this multi-center study will increase the current knowledge of PD and that the identification of factors that cause PD will lead to better diagnosis and treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Young onset PD patients
Criteria

Inclusion Criteria:

  • Any person with Parkinson's disease in the United States whose symptoms began at age 50 or younger and was diagnosed by a neurologist.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00104585

Locations
United States, California
The Parkinson's Institute
Sunnyvale, California, United States, 94089
United States, Connecticut
The Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Glenbrook Hospital, Evanston
Glenview, Illinois, United States, 60026
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Minnesota
Struthers Parkinson's Center
Golden Valley, Minnesota, United States, 55427
United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Columbia University
New York, New York, United States, 10032
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Rhode Island
Neuro Health
Warwick, Rhode Island, United States, 02886
United States, Tennessee
University of Tennessee Health Science Center
Memphis, Tennessee, United States, 38136
United States, Wisconsin
Marshfield Clinic
Marshfield, Wisconsin, United States, 54449
Sponsors and Collaborators
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Karen Marder, M.D., M.PH. Columbia University
  More Information

Responsible Party: Columbia University
ClinicalTrials.gov Identifier: NCT00104585     History of Changes
Other Study ID Numbers: AAAA5609  R01NS036630 
Study First Received: March 1, 2005
Last Updated: January 18, 2012
Health Authority: United States: Federal Government

Keywords provided by Columbia University:
Parkinson's disease
PD
gene
environment
early-onset Parkinson's disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on December 07, 2016